CSCO 2024: Dr. Jun Zhu Spearheads China’s Breakthroughs in Anti-Tumor Drug Development

CSCO 2024: Dr. Jun Zhu Spearheads China’s Breakthroughs in Anti-Tumor Drug Development

From September 25 to 29, 2024, the 27th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was successfully held in Xiamen. Themed Patient-Centered, Sharing the Future, the conference brought together major research advancements and developments from both domestic and international spheres. Over the past two decades, CSCO has been a continuous leader in the development of clinical oncology in China, with numerous experts and scholars contributing to and benefiting from CSCO’s growth. In response to CSCO's initiative, Hematology Frontier established the Growing with CSCO column to look back at the history of this organization alongside Chinese scholars. This issue features an exclusive interview with Dr. Jun Zhu, Vice President of the CSCO Council and Professor at Peking University Cancer Hospital, where he shares his journey of growing with CSCO and highlights the progress and achievements in the field of lymphoma in China.
Decoding Gene Silence: Nobel Honors Pioneers of microRNA in Blood Cancer Therapies

Decoding Gene Silence: Nobel Honors Pioneers of microRNA in Blood Cancer Therapies

The 2024 Nobel Prize in Physiology or Medicine has once again brought the spotlight onto the field of gene regulation. This year, American scientists Victor Ambros and Gary Ruvkun were honored with the prestigious award for their pioneering research on microRNA and its role in post-transcriptional gene regulation. Their groundbreaking discoveries not only opened new horizons in understanding gene regulation but also offered new perspectives and methods for studying and treating hematological diseases such as leukemia.
3D Surgery Breakthrough: Dr. Renquan Zhang Talks Innovative Treatment for Elderly Esophageal Cancer Patients

3D Surgery Breakthrough: Dr. Renquan Zhang Talks Innovative Treatment for Elderly Esophageal Cancer Patients

From September 26 to 28, 2024, the China Anti-Cancer Association (CACA) and the CACA Integrative Esophageal Cancer Committee hosted the 2024 CACA Integrative Esophageal Cancer Academic Conference in Hefei. This prestigious event gathered leading experts in the field of esophageal cancer from China and abroad. The topics ranged from cancer prevention, early diagnosis and treatment, standardized therapy, and integrated treatment approaches. Oncology Frontier had the opportunity to interview Dr. Renquan Zhang from The First Affiliated Hospital of Anhui Medical University (AMU) to discuss advancements in the diagnosis and treatment of esophageal cancer. Below is a summary of the interview for our readers.
Mao Leads the Way: A New Era in Esophageal Cancer Treatment Commenced at CACA Conference

Mao Leads the Way: A New Era in Esophageal Cancer Treatment Commenced at CACA Conference

From September 26 to 28, 2024, the "2024 China Anti-Cancer Association Integrated Esophageal Cancer Academic Conference" was held grandly in Hefei, hosted by the China Anti-Cancer Association (CACA) and the CACA Integrated Esophageal Cancer Committee, with five subcommittees on esophageal cancer joining forces with Anhui Medical University's First Affiliated Hospital. Alongside, the "16th China Anti-Cancer Association Esophageal Cancer Conference" also took place.
Breaking News: ISDE 2024 Spotlights Groundbreaking Predictive Vital Sign Tech for Esophageal Cancer Surgery

Breaking News: ISDE 2024 Spotlights Groundbreaking Predictive Vital Sign Tech for Esophageal Cancer Surgery

From September 22nd to 24th, 2024, the 20th International Society for Diseases of the Esophagus (ISDE) conference was grandly held in Edinburgh, Scotland. A study by Dr. Andrew Seely from the University of Ottawa's Faculty of Medicine on predictive vital sign monitoring during the perioperative period for esophageal cancer was selected for abstract presentation at the conference (Abstract No.: S19.05). Oncology Frontier conducted an exclusive interview with Prof. Seely at the conference venue to discuss his research.
Filipa Fonseca Challenges Traditional EGJ Cancer Classification with Innovative Approach at ISDE 2024

Filipa Fonseca Challenges Traditional EGJ Cancer Classification with Innovative Approach at ISDE 2024

From September 22nd to 24th, 2024, the 20th International Society for Diseases of the Esophagus (ISDE) conference was grandly held in Edinburgh, Scotland. Dr. Filipa Fonseca from the Lisbon Oncology Research Center presented a study on the modified Siewert classification for adenocarcinoma of the esophagogastric junction (EGJ) at the Late-Breaking Oral Abstract session (Abstract No.: LB-OA02.07), which sparked extensive discussion and interest. Oncology Frontier conducted an exclusive interview with Prof. Fonseca at the conference venue regarding this classification method.
Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future

Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future

Neo-AEGIS Study Unveils: Peroperative Chemo Stands Tall in Esophageal Cancer Treatment, Signaling a Customized Future Editor's Note: From September 22nd to 24th, 2024, the 20th International Esophageal Cancer Conference (ISDE) took place in Edinburgh, Scotland. The Neo-AEGIS study, which compared the efficacy of perioperative chemotherapy with the CROSS regimen (preoperative chemotherapy combined with radiotherapy) in the treatment of esophageal cancer, captured global attention. As the corresponding author of the study, Dr. John Reynolds from St. James's Hospital in Ireland provided an in-depth interpretation of the research findings and discussed their profound impact on future strategies for esophageal cancer treatment.
ISDE 2024 | Groundbreaking: Prehabilitation Transforms Borderline Resectable Esophageal Cancer Patients into Surgical Candidates

ISDE 2024 | Groundbreaking: Prehabilitation Transforms Borderline Resectable Esophageal Cancer Patients into Surgical Candidates

The 20th International Society for Diseases of the Esophagus (ISDE) conference took place in Edinburgh, Scotland, from September 22nd to 24th, 2024. At the conference, a study by Dr. Krishna Moorthy from the Royal College of Surgeons in the UK on whether prehabilitation can increase the surgical opportunities for esophageal cancer patients was selected for presentation (Abstract No.: S19.02). Oncology Frontier conducted an exclusive interview with Professor Moorthy at the conference venue about this research. The interview content has been organized and the relevant study abstract is attached for reference.
Integrative Medicine Shines at CACA: Dr. Liu Hong Outlines New Horizons in Esophageal Cancer Treatment

Integrative Medicine Shines at CACA: Dr. Liu Hong Outlines New Horizons in Esophageal Cancer Treatment

From September 26 to 28, 2024, the China Anti-Cancer Association (CACA) and the CACA Integrative Esophageal Cancer Committee hosted the 2024 CACA Integrative Esophageal Cancer Academic Conference in Hefei. The conference, under the theme “Winning in Integration for Cancer Prevention and Treatment,” gathered the latest research developments and clinical experiences from experts in esophageal cancer worldwide. During the event, Oncology Frontier had the opportunity to interview Dr. Liu Hong from The First Affiliated Hospital of Air Force Medical University (Xijing Hospital). In this interview, Professor Hong delves into the trends of integrative treatment, individualized care, and the importance of comprehensive patient management. Below is the full transcript of the interview for our readers.